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challenges. Self-administered questionnaires were used and data were analyzed 
with SPSS version 16. Results: The mean age was 16.9 ± SD 2.5 and 21 (62%) were 
mainly females and in school. Four were in primary school, 14 in junior secondary 
school, 12 in senior secondary and another 4 in tertiary institutions. Most (85%) 
were aware that young people their age could fall sick, 91% had heard of HIV, 70% 
knew someone with HIV and 45 % thought that adolescents were not at risk of HIV. 
Eighteen (52.9%) knew their HIV status, 17 (50%) were on antiretroviral and 32% of 
these admitted to missing Anti-Retroviral (ARVs) dose. ConClusions: Disclosure 
of HIV status to adolescents and young people is dependent on a complex mix of 
factors and most practitioners recommend an age and developmentally appropriate 
disclosure. The knowledge and awareness of HIV was 91%. There is also the need to 
support care givers to disclose HIV status and to support young people to adhere to 
ARVs for better outcomes. KeywoRds: Knowledge; Disclosure Adolescents/Young 
Adults; HIV, Ghana.
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ImPlemeNtatIoN of techNologIes Based oN the evIdeNce-Based 
medIcINe aNd hta IN the maNagemeNt of hePatItIs c
Lishchyshyna O., Melnyk Y., Migel O.
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objeCtives: The health care system of Ukraine is being transformed according to 
the modern world format. More and more doctors are aware of the need for the use 
of technologies based on evidence-based medicine, particularly in the management 
of hepatitis C. Methods: In 2013 the multidisciplinary working group involving 
professionals and patients developed an adapted clinical guideline, based on HTAs 
and strategies of evidence-based medicine on the treatment of hepatitis C, and uni-
fied clinical protocol “Viral hepatitis C”. Results: The differences in the treatment 
of hepatitis C in Ukraine compared to the best international practice were revealed 
and considered while developing medical and technological documents for health 
care in hepatitis C. Doctors and the public were informed of modern evidence-based 
technologies concerning management of the hepatitis C. As a result, the multidis-
ciplinary working group adapted these documents of best methodological quality. 
Introduction of these documents reorients doctors on a modern approach to the 
assessment of scientific medical information. The unified clinical protocol contains 
provisions for minimum acceptable quality of primary and specialized medical care 
and the algorithms of patient’s identification. ConClusions: Provision of changes 
in the current medical practice is associated with the introduction of modern medi-
cal technologies based on evidence-based medicine. Ukraine has implemented the 
algorithm for the use of best practice: a multidisciplinary working group adapts 
clinical guidelines based on evidence → creates unified clinical protocols → each 
health institution develops local protocols, taking into account the resources of a 
health facility and interaction of these institutions.
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objeCtives: The prevalence of the hepatitis C virus (HCV) remains high amongst 
people who inject drugs (PWID) and accounts for the majority of newly acquired infec-
tions. This study aims to quantify the value of treatment amongst PWID with new 
direct acting antivirals (DAAs) at increased uptake rates, with respect to the avoidance 
of future infections and subsequent long-term complications of HCV. Methods: A 
dynamic HCV transmission and disease progression model was developed, incorpo-
rating acute and chronic infection and their long-term complications (decompensated 
cirrhosis, cancer, liver transplant and mortality), with the potential for reinfection 
following treatment failure. The model was populated with prevalence and therapy 
data from a UK setting. Scenarios of current standard of care (SoC) treatment efficacy 
and uptake were compared to anticipated sustained virologic response (SVR) rates 
of 90–100% and increased uptake over varied horizons. Results: SoC led to modest 
reductions in prevalence; > 5% after 200 years. New treatments achieving 90% SVR 
could reduce prevalence below 5% within 60 years at current uptake rates or within 5 
years if all patients are treated. Amongst 4,240 PWID, chronic HCV infections avoided 
as a result of increasing treatment uptake over the period 2015–2027 ranged from 
20–580 and 34–912 with SoC and 90% SVR rates respectively. The reduction in down-
stream HCV infections due to increasing treatment uptake resulted in an approximate 
discounted gain of 300 life-years (from avoiding reduced life expectancy from HCV 
infection) and a gain of 1,700 QALYs (from avoiding the disutility of HCV infection 
and related complications), with a projected £5.4 million cost saving. ConClusions: 
While improved SVR profiles led to reductions in modelled prevalence, increased 
treatment uptake was the key driver of future infections avoided. Increased treatment 
among PWID, with new more efficacious therapies, could significantly change the 
future dynamics, cost and health burden of HCV-related disease.
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PRescRIPtIoN PRactIces foR uNcomPlIcated malaRIa at two PuBlIc 
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objeCtives: Poor adherence to treatment guidelines undermines the goals of 
malaria treatment with implications for worsening malaria burden. This study 
analyzed the diagnostic and prescription practices for uncomplicated malaria at 
two levels of public health facilities in Nigeria, to assess the current state of compli-
ance to policy. Methods: Retrospective audit of patients’ records for uncompli-
cated malaria was carried out at a primary/secondary and tertiary health facilities. 
Demographics, diagnostic information, medication and cost data were extracted. 
Data from the two facilities were analyzed and compared for similarities and 
monitor and to correlate HRQL improvements in patients undergoing different 
treatment strategies.
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ImPact of sImePRevIR veRsus telaPRevIR tRIPle theRaPy foR chRoNIc 
hcv INfectIoN oN PatIeNt-RePoRted outcomes IN PRIoR NoN-
ResPoNdeRs to PegINteRfeRoN/RIBavIRIN Results fRom the Phase III 
attaIN study
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1Janssen Global Services, LLC, High Wycombe, UK, 2Janssen Research and Development, Beerse, 
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objeCtives: In ATTAIN, a Phase III, randomised, head-to-head comparison study 
of simeprevir versus telaprevir, both with peginterferon/ribavirin (PR), in HCV gen-
otype 1-infected prior null or partial PR responders, simeprevir exhibited better 
safety and tolerability. In this analysis, the impact on patient-reported outcomes 
(PRO) was analysed. Methods: Patients received simeprevir (150mg QD) or tel-
aprevir (750mg TID, 7-9hrs apart) +PR for 12wks followed by PR alone (36wks) in 
a double-blind, double-dummy design. PRO questionnaires, completed at base-
line, throughout treatment and at follow-up, rated fatigue severity (FSS), depres-
sive symptoms (CES-D), work and daily activities impairment (WPAI: Hepatitis-C), 
health-related quality of life (EQ-5D visual analogue scale), and skin symptoms 
(Skindex-16). During simeprevir/telaprevir treatment, between-treatment mean-
value differences were calculated using area-under-the curve to Wk12 (AUC12) for 
all measures except Skindex-16 where maximum (worst) scores during the first 12 
wks were used. Subgroup analyses evaluated the impact of SVR12, age, fibrosis and 
treatment completion. Results: Compared with normative studies, baseline PRO 
scores indicated greater fatigue, depressive symptoms and daily activities impair-
ment. Mean PRO scores in both groups worsened during the first 12 weeks of treat-
ment, remained stable through Week 48 and returned to values close to baseline at 
end of treatment. Clinically relevant between-treatment differences in FSS, CES-D, 
Skindex-16 and EQ-5D scores indicated less impairment with simeprevir than tel-
aprevir. AUC12 between-treatment differences significantly favoured simeprevir 
for FSS (p= 0.003), WPAI Activity Impairment (p= 0.022), and EQ-5D (p< 0.001). Mean 
Skindex-16 maximum total (p= 0.0087) and subscale scores were significantly lower 
for simeprevir. Subgroup analyses showed less impairment with simeprevir versus 
telaprevir on most PRO scores in patients who failed treatment, were > 45 years old 
or had advanced fibrosis. ConClusions: Simeprevir/PR resulted in less fatigue, 
depressive and skin-related symptoms and less impairment in daily activities than 
telaprevir/PR. These findings provide valuable information on the tolerability of 
these regimens from the patient perspective.
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easteRN NIgeRIaN hosPItals
Ekwunife O.I.
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objeCtives: The greatest burden of the HIV infection is felt in sub-Saharan Africa. 
Nigeria is rated among the first three largest countries with HIV population. 
Pharmacists play an important role in the care of HIV patients especially by provid-
ing pharmaceutical care. Thus it is imperative to assess the experience and satisfac-
tion of HIV patients with the pharmaceutical services they receive as this will ensure 
that quality care is rendered. The objective of this study was to assess HIV-infected 
patients’ satisfaction with pharmacy services provided in South-Eastern Nigeria’s 
HIV/AIDS clinics. A secondary aim was to repeat the validation process in order to 
confirm the initial validation of PSPS questionnaire. Methods: The survey was 
conducted in 6 HIV/AIDS clinics in South-Eastern Nigeria. Multi-stage sampling 
technique was used to select the clinics. Re-validation techniques employed include 
factor analysis, reliability test, and construct validity. The level of satisfaction of the 
participants was determined. Variance in satisfaction score among the different 
demographic variables was also assessed. Results: The response rate was 81.85%. 
The Cronbach alpha value was 0.84. The 16 items of PSPS questionnaire resolved 
into 4 factors as established by the initial validation exercise. Re-validation of the 
PSPS Questionnaire’s construct revealed the same result obtained in the original 
validation as items that were related showed convergence while items that were 
not related showed divergence. With the exception of item 12, the average score 
obtained in the survey was high. Most of the average scores ranged from 4 to 5, 
signifying that responses ranged from agree to strongly agree. ConClusions: HIV 
patients were highly satisfied with services rendered by the pharmacists in South-
Eastern HIV clinics in Nigeria and PSPS proved to be a reliable and valid instrument 
for measuring satisfaction of HIV patients with pharmacy services.
INfectIoN – health care use & Policy studies
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atteNdINg aN adolesceNt hIv clINIc IN accRa, ghaNa
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objeCtives: In Ghana it is estimated that 1.7% of HIV infections occur in young 
people aged 15-24. Despite this the representation of young people in our clinics is 
small. Adherence to treatment, appointment keeping and knowledge of HIV status 
remain a challenge. Disclosure has been shown to confer the following benefits. 
The study sought to assess the knowledge of HIV status of adolescents and young 
adults. Methods: A baseline study was conducted to ascertain if adolescents and 
young adults knew their HIV status and also determine their knowledge on HIV in 
general with 34 participants. An adolescent club was established to engage with 
young people, provide better tailored care and support and to solve their peculiar 
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suggest that PIM is a cost-effective treatment strategy compared to OTT for HIV-1 
infected patients who have achieved sustained virological suppression.
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(ses)
Gemio Zumalave P.1, Carmona Torres C.1, Domínguez Rodríguez J.C.1, Sánchez Chorro J.L.1, 
Hidalgo A.2, Vigara Cruces J.M.1
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objeCtives: Evaluate the cost associated with the ADRs from the use of boceprevir 
(BOC) or telaprevir (TLP) in patients treated with protease inhibitors (PI) in the 
SES. Methods: A multicenter observational study of cohort ITT, extracting the nec-
essary data from the information systems of SES, from September 2012 to December 
2013, for patients treated with TLP or BOC was performed. Those co-infected patients 
(HIV or HBV), in liver transplant or with history of hepatocellular carcinoma were 
excluded. ADRs assessed were alopecia, fever, retinitis, itching, weight loss, rash, 
thrombosis, neutropenia, hemorrhoids, stomach pain, amenorrhoea, arthralgia, 
anxiety and the number of infiltrated blood received by patients. To assess the 
pharmaceutical cost of ADRs the retail price + VAT at Official List were taken, and to 
other public health costs SSPE prices, the NHS and records of unit costs were taken 
also. Results: Withdrawals caused by ADRs were higher for TLP (12.2% vs 8.1%, 
p = 0.09), frequency of pruriginous erythema (44.9% vs 4%, p < 0.001) and anemia 
(69.4 % vs. 52%, p = 0.142). For BOC, there were higher percentages of dysgeusia (16% 
vs. 0%, p = 0.011), and neutropenia (52% vs. 24.5%, p = 0.018). The results showed a 
significant difference between the treatment cost per patient associated with ADRs 
caused by BOC (€ 5,896) compared to the TLP (€ 11,234), for 34.7 weeks (BOC) and 25.9 
weeks (TLP). ConClusions: In view of the results obtained, it shows that means a 
lower costs for the health system ―in the treatment of ADRs due to the use of PI in 
patients with hepatitis C― patients receiving BOC versus TLP. Postmarketing obser-
vational studies are needed to determine the actual efficacy and safety of new drugs.
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PRImaRy caRe PhysIcIaNs IN aN INteRfeRoN-fRee woRld: could safeR, 
moRe efectIve oRal hePatItIs c theRaPIes lead to ImPRoved outcomes 
thRough educatIoN aNd PcP-PRescRIBed tReatmeNt?
Levine-Wilkinson S.R., Holman D.W., Cummings H.E.
Decision Resources Group, Burlington, MA, USA
objeCtives: Hepatitis C virus (HCV) treatments have been improved by the 
availability of highly effective and well-tolerated interferon-free therapies. This 
study probes the impact of such therapies on the role of primary care physicians 
(PCPs) in diagnosis, referral, and treatment of HCV patients who have historically 
been treated by gastroenterologists and hepatologists. Methods: In the U.S., 
100 PCPs, 51 specialists (44 gastroenterologists, 7 hepatologists), and 30 Managed 
Care Organization (MCO) pharmacy directors/medical directors (PDs/MDs) were 
surveyed to assess PCP knowledge of and involvement in HCV diagnosis and 
screening, referral patterns, and treatment options. Results: Survey results 
identify referral to specialists as a notable barrier to accessing care. Some 77% 
of PCPs who follow-up with patients they refer to HCV specialists estimate that 
24% are lost to follow-up. Similarly, 73% of specialists report having PCP-referred 
patients who missed their exam, and these specialists estimate that 15% of all PCP-
referred patients “drop off”. In anticipation of multiple new HCV therapies reach-
ing the major markets, several professional societies have collaborated to develop 
expert-curated, regularly updated guidelines providing clinical recommendations 
for diagnosing and treating HCV patients (www. hcvguidelines. org). Among sur-
veyed PCPs, 74% were unaware of these guidelines; however, once informed, 63% 
of all PCP respondents indicated greater comfort with prescribing treatments rec-
ommended by these guidelines. Furthermore, 63% of MCO PDs/MDs and 98% of 
HCV specialists surveyed reported feeling more comfortable with PCPs prescribing 
these recommended treatments. ConClusions: The substantial decline in the 
cascade of care from PCP referrals to specialists suggests that educating PCPs on 
new interferon-therapies presents an opportunity to maximize retention in care 
and accelerate efforts to identify undiagnosed cases. Survey responses from PCPs, 
as well as specialists, and MCO PDs/MDs suggest that practical, regularly updated 
clinical guidelines prepared by international experts could provide a common 
framework for educational outreach efforts to PCPs.
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ReducINg vaRIcella wIth RoutINe chIldhood vaccINatIoN IN Italy?
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objeCtives: Policymakers may have a concern that a long time interval between 
two doses, partial efficacy and potential waning after the first dose of varicella 
vaccination would reduce the impact of a universal childhood varicella immuni-
zation program. The objective of this study is to determine the potential impact 
and relative weight of 2 key factors: (1) coverage and (2) vaccine efficacy (VE) of 
the first dose of varicella vaccination (VE-D1) in the context of long term interval 
between two doses on varicella epidemiology in Italy. Methods: An age-structured 
dynamic transmission model is adapted and fitted to the seroprevalence of varicella 
in Italy in absence of vaccination. Vaccination is introduced with 1- and 2-dose VE, 
with long time interval between 2 doses (given at 13 months and 6 years of age). 
Several scenarios are tested including 2 levels of VE-D1 (65%/75%) and 3 coverage 
levels (95%/80%, 85%/70%, 75%/60%, respectively). Efficacy post-dose 2 is fixed at 
95%. Results: For a vaccine coverage of 95%/80%, the reduction in number of vari-
cella cases compared with the absence of vaccination for 75% and 65% VE-D1 was 
respectively 89.2%/87.5% by year 30, and 78.9%/74.6% by year 80 after vaccination 
program initiation. For a vaccine coverage of 85%/70%, the reduction in number of 
systematic differences, and conformity to malaria treatment policy, in terms of 
the use of ACT, accuracy of diagnosis, concomitant medication and cost of medi-
cation. Results: 2,171 patients’ records were analyzed. 986 (46%) were sent for 
laboratory confirmation using microscopy, out of which only 45% tested positive. 
Majority of prescriptions, 54% was on the basis of presumptive treatment. 58% of 
slide negative results received antimalarials. Gender disparity was significant; 1207 
(56%) females, 942 (43%) males. 93% of prescriptions contained ACTs with AL as the 
most frequently prescribed antimalarial drug. Monotherapy accounted for 7% of 
the prescriptions. 97% (1722) of prescriptions received at least one co-medication, 
mostly analgesics, vitamin preparations and antibiotics. Antibiotics were given to 
50% of patients, with children under five most likely to be co-prescribed antibiot-
ics. Overall, median cost of medication was US$7.34 (US$0.16 – 262.78) per case. 
There were significant variations in treatment practices between the two facili-
ties. ConClusions: Evidence suggest high rate of compliance to policy on the 
use of ACT as first line treatment for uncomplicated malaria but there is significant 
scope for improved diagnosis and prescription to enhance accuracy of treatment 
and reduced wastages, especially at the medical center. Regular updates of providers 
on appropriate practices are needed to improve adherence to treatment guidelines 
for enhanced efficiency of malaria treatment in Nigeria.
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objeCtives: To describe real-world treatment patterns, health care resource use, 
and opportunities for early switch (ES) from intravenous (IV) to oral antibiotics 
and early discharge (ED) for patients hospitalized in the United Arab Emirates 
(UAE) with methicillin-resistant Staphylococcus aureus (MRSA) complicated skin 
and soft-tissue infections (cSSTIs). Methods: This retrospective observational 
medical chart review study enrolled physicians from four UAE sites to collect data 
for 24 total patients with documented MRSA cSSTI, hospitalized between July 2010-
June 2011, and discharged alive by July 2011. Data include clinical characteristics 
and outcomes, hospital length of stay (LOS), MRSA-targeted IV and oral antibiotic 
use and ES and ED eligibility using literature-based and expert-validated crite-
ria. Results: For all patients, the actual length of MRSA-active treatment was 
10.8±7 days, with 9.8±6.6 days of IV therapy, and mean LOS 13.9±9.3 days. The most 
frequent initial MRSA-active therapies used were vancomycin (33.3%), linezolid 
(16.7%), and clindamycin (16.7%). Five patients (20.8%) were switched from IV to 
oral antibiotics while inpatient. Eight patients were discharged with MRSA-active 
antibiotics, with linezolid prescribed most frequently (n= 3; 37.5%). Fifteen patients 
(62.5%) met ES criteria and potentially could have discontinued IV therapy 8.3±6.0 
days sooner. Eight patients (33.3%) met ED criteria and potentially could have 
been discharged 10.9±5.8 days earlier. Assuming an average cost of 2,691 dirhams 
($575)/bed day in the UAE, the total savings would be 29,332 dirhams ($6,268) in 
bed-day cost savings realized per ED-eligible patient. ConClusions: While one 
fifth of patients were switched from IV to oral antibiotics in the UAE, there were 
clear opportunities for further optimization of health care resources. Over half of 
UAE patients hospitalized for MRSA cSSTI could be eligible for ES and one-third 
eligible for ED opportunities, resulting in the potential for a substantial reduction 
in IV days and bed days.
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objeCtives: To estimate the cost-effectiveness of a strategy of switching the 
antiretroviral therapy (ART) to protease inhibitor monotherapy (PIM) with prompt 
return to combination therapy in the event of viral load rebound compared to con-
tinuing the ongoing triple therapy (OTT) in the long-term management of HIV-1 
infected patients. Methods: Within trial cost-effectiveness analysis and modelling 
of life-time cost-effectiveness based on a randomised controlled trial of Protease 
Inhibitor monotherapy Versus Ongoing Triple-therapy (PIVOT). The setting was 
HIV outpatient care in the UK National Health Service and the trial involved 587 
patients, aged 18 years or more, who achieved sustained virological suppression 
and have a CD4+ cell count > 100 cells/mm3. Outcomes were NHS costs (2012 UK 
Pounds Sterling) and quality-adjusted life-years (QALY) with comparative results 
presented as incremental cost-effectiveness ratios (ICERs). Results: Overall, PIM 
was cost-effective compared to OTT. PIM was cost-saving due to large savings in 
the ART drug costs while being no less effective in terms of QALYs in the within 
trial analysis and only marginally less effective with modelling. In the base-case 
within-trial analysis, the incremental total cost per patient was -£6,424.11 (95% 
confidence interval: -£7,418.84 to -£5,429.38) and the incremental QALY was 0.0051 
(95% confidence interval: -0.0479 to 0.0582) making PIM dominant compared to 
OTT. Multiple sensitivity analyses were conducted to assess the importance of 
assumptions surrounding drug costs, missing data, trial protocol driven costs and 
mortality. In all sensitivity analyses, PIM was cost-saving and no marked difference 
in QALY was observed. Modelling of life time costs and QALYs showed significant 
cost-savings and marginally less effectiveness such that switching to PIM appeared 
cost-effective at accepted cost-effectiveness thresholds. ConClusions: The results 
